精確搜索結(jié)果
- Products
- Applications and Industries
- 內(nèi)容類型
- Analysis Platform
- 語言
1 - 12 共 12 條結(jié)果
應(yīng)用的篩選條件
This application note evaluates the Agilent xCELLigence RTCA eSight as a tool to monitor BiTE antibody-mediated cancer cell lysis.
This study used the Agilent xCELLigence RTCA CardioECR system with human iPSC-derived cardiomyocytes (hiPSC-CMs) to evaluate cardiac safety/toxicity of antiviral drugs.
A demonstration of the use of the Agilent xCELLigence RTCA CardioECR system to compare functional profiles of contractility and electrophysiology between an PS-iPSC-CM disease model and its isogenic control.
Noninvasive and continuous monitoring of the perturbation of cellular growth following exposure to the cumulative toxicants present in water samples.
A demonstration of how the Agilent xCELLigence RTCA eSight real-time imaging platform can be used to monitor induction of the unfolded protein response using a genetically encoded fluorescent sensor.
A demonstration of how the Agilent xCELLigence RTCA eSight real-time imaging platform can be used to monitor phagocytosis, using a model system comprising macrophages and E. coli cells conjugated to a pH-sensitive fluorescent dye.
A demonstration of how the eSight combines the strengths of real-time impedance monitoring with those of live cell imaging, to increase the information richness of your proliferation assays while simultaneously reducing the workload.
To determine if the stimulation of endogenously expressed GPCRs can be monitored by the xCELLigence system, cells were stimulated with various receptor agonists, triggering either Gs-, Gi-, or Gq-mediated downstream signals.
Using the Agilent xCELLigence RTCA eSight to continuously monitor CAR T cell-mediatedkilling of cancer cells over the course of multiplae days.
This application note presents a method for improving human-induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) maturation using the Agilent xCELLigence RTCA ePacer system.
In this application note, we used the xCELLigence RTCA CardioECR system (CardioECR system) in conjunction with hiPS-CMs for the assessment of preclinical cardiac risks.
Using the Agilent xCELLigence RTCA system to assess both the selectivity and potency of the TCR-engineered TILs toward HLA restricted cells.